As women approach menopause, the thinning of bones can lead to fractures, a significant concern for long-term health. Recent research has shown that a single infusion of zoledronate—a medication that slows bone loss—can make a difference. In a groundbreaking study published in the New England Journal of Medicine, women in their 50s with below-average bone density (T-score < 0) experienced ~30% fewer fractures over a 10-year period. These findings support the use of zoledronate as a potential strategy for fracture prevention in postmenopausal women at risk for osteoporosis-related fractures.